[4 min read] Dermoscopic criteria differentiation between BCC and Bowen’s disease

BCC

The dermoscopic features of superficial basal cell carcinoma (BCC) and Bowen’s disease have been extensively investigated, and dermoscopy was shown to significantly improve their recognition. However, incorrectly diagnosed cases still exist, with a considerable number of BCCs dermoscopically interpreted as Bowen’s disease. Continue reading “[4 min read] Dermoscopic criteria differentiation between BCC and Bowen’s disease”

[3 min read] Risk of skin cancer in patients with HIV

HIV and skin cancer
What is the risk of skin cancer in patients with HIV? The risk of skin cancer in patients with human immunodeficiency virus (HIV) has not been extensively studied. A Danish study sought to determine the risk of skin cancer in patients with the virus, and compare it with the risk in the non-HIV population.

Continue reading “[3 min read] Risk of skin cancer in patients with HIV”

[4 min read] How will artificial intelligence benefit GPs in skin cancer medicine?

Artificial intelligence

Yes, the robots are coming! This month I share an article published in PLOS One in March this year. There is now a steady stream of research papers showing how Artificial Intelligence (AI) is effective in accurately diagnosing skin cancers. Continue reading “[4 min read] How will artificial intelligence benefit GPs in skin cancer medicine?”

[3 min read] Are negative margins in BCC biopsies an accurate predictor of residual disease?

margins

Pathology reports of basal cell carcinoma biopsies often contain comments of positive or negative margins, with only one to two per cent of the margin evaluated. A recent study sought to determine the negative predictive value of basal cell carcinoma biopsy margin status on the absence of residual basal cell carcinoma in the corresponding excision.

Continue reading “[3 min read] Are negative margins in BCC biopsies an accurate predictor of residual disease?”

[Review] Skin Cancer Summit & Masterclasses 2018

 

25 – 28 July 2018 | Brisbane 

The 10th Skin Cancer Summit & Masterclasses saw international thought leaders in skin cancer medicine converge in Brisbane to collaborate with GPs from across Australia. The 2018 program once again covered a broad range of topics relevant to doctors working in primary care skin cancer medicine. The Masterclasses focused on core day-to-day material, as a way to reinforce and extend knowledge. The two-day Summit opened up new areas of study, enquiry and interest.

      

 

Dermoscopy Masterclass: 25 July 2018

The first Masterclass focused on diagnosis through dermoscopy and was run by Prof Ash Marghoob (USA) and Dr Aimilios Lallas (Greece).

Dr Lallas used the concept of false positive and false negative diagnoses to reinforce our diagnostic accuracy. Clearly, as morphology overlaps the distinction between what is a cancer, and what is not, can provide confusion.

This broad concept was beautifully extended by Prof Marghoob through his presentation on difficult to diagnose melanomas. As we all know, the easy ones are easy. It is the hard-to-diagnose that we risk missing!

The session then moved into important body sites – the face and acral areas, which are important because the morphology of lesions on these sites is different from morphology on other sites. If we don’t understand this and know how the appearances differ, then we can’t accurately recognise cancers.

Our presenters then extended these important concepts to difficult to diagnose non-melanoma skin cancers, as it is not just melanomas that can be tricky. And, as always, we finished with a series of interactive cases.

 

Surgery Masterclass: 26 July 2018

The second Masterclass covered surgery of the ear. The ear, of course, is a common site for skin cancer because it is so exposed to solar damage. Ear surgery is important because cosmetic results are very visible to the patient and others. So, it is essential to get the surgery right, cure the cancer, and repair the defect as sympathetically as possible.

Dr Con Pappas and Dr Tony Azzi provided a comprehensive overview of how to prepare for and conduct surgery of the ear, across almost all imaginable lesions.

 

Summit: 27-28 July 2018

    

The Summit program is deliberately designed to be a mix of very practical, everyday material that supports our daily practice.

This year, key examples of these sessions were those on ‘effectiveness of dermoscopy’, ‘why we miss melanoma’, and ‘radiation oncology’. We also ran sessions that we hope will keep you and your patients safe, including ‘what interests the watchdog’ and ‘monitoring tips and traps’.

      

We deliberately moved into the future and sought to explore and speculate on what might be. It is clear that artificial intelligence is already with us, and yet most of us don’t really see what is happening and what might be coming. As educated and interested professionals, it is worth being aware of these trends.

We also like to keep you across what is happening outside clinical practice, in areas that are relevant to running your business. So, our sessions on how to run a successful business, and how others organise their own practices, are always very popular.

 

Skin Cancer Institute Gala Dinner

The Skin Cancer Summit closed with a Gala Dinner at the Queensland Cricketers’ Club. Hosted by the Skin Cancer Institute, the inaugural ‘White Out Skin Cancer’ Gala Dinner donated all proceeds to QIMR Berghofer. The delegates’ generosity and support will make a difference to many lives as we take a step closer to our vision of a world where nobody dies from skin cancer.

 

11th Skin Cancer Summit and Masterclasses 2019

Plans are well underway for the 11th Skin Cancer Summit & Masterclasses in 2019! Save the date for 21-24 August 2019 and learn more here.

Skin Cancer Update with Prof Giuseppe Argenziano [October 2018]

skin cancer update

Professor Giuseppe Argenziano gives a skin cancer update in which he shares the results of recent research into methotrexate in the treatment of advanced squamous cell carcinoma. Continue reading “Skin Cancer Update with Prof Giuseppe Argenziano [October 2018]”

Does hydrochlorothiazide use increase risk of non-melanoma skin cancer?

hydrochlorothiazide

[2 min read] Hydrochlorothiazide is photosensitising and has previously been linked to lip cancer. The drug is commonly used in Australia to treat hypertension and oedema, and is one of the most frequently used diuretic and anti-hypertensive drugs in the United States and Western Europe.

A Danish study looked at the association between hydrochlorothiazide use and the risk of basal cell carcinoma and squamous cell carcinoma. Continue reading “Does hydrochlorothiazide use increase risk of non-melanoma skin cancer?”

Radiotherapy in patients with non-melanoma skin cancers

radiotherapy

Is radiotherapy an effective adjuvant treatment for non-melanoma skin cancers of the head and neck? This was explored in a study published in the International Journal of Dermatology, with a particular focus on the efficacy and outcomes of the therapy for elderly patients. Continue reading “Radiotherapy in patients with non-melanoma skin cancers”

What therapies are emerging for squamous cell carcinoma?

squamous cell carcinoma

What therapies are emerging in the treatment of cutaneous squamous cell carcinoma?

Deaths from cutaneous squamous cell carcinomas may outnumber deaths from melanoma in both Australia and USA. While great advances have been made in targeted management of advanced melanoma and advanced basal cell carcinoma, targeted treatment of advanced cutaneous squamous cell carcinoma has lagged behind. Continue reading “What therapies are emerging for squamous cell carcinoma?”

Case discussion: How would you treat this patient? [25 June]

Case discussion

This week we have an engaging case from Dr Tim Aung. An 70-year-old male with two distinct pigmented skin lesions were found on the face, as shown.

What is your evaluation of the clinical and dermoscopic images? What would you do next?

Continue reading “Case discussion: How would you treat this patient? [25 June]”